Astrazeneca's Lynparza capsules given green light from European Commission
British pharmaceutical giant AstraZeneca has received marketing authorisation from the European Commission for its Lynparza cancer treatment.
AstraZeneca
11,946.00p
09:00 25/04/24
FTSE 100
8,077.57
09:00 25/04/24
FTSE 350
4,434.67
09:00 25/04/24
FTSE All-Share
4,388.38
09:00 25/04/24
Pharmaceuticals & Biotechnology
22,636.60
09:00 25/04/24
The firm said the capsules will be used to treat adult patients suffering from epithelial ovarian, fallopian tube, or primary peritoneal cancer who respond fully or partially to platinum-based chemotherapy.
AstraZeneca said the move would help patients with BRCA-mutated ovarian cancer whose options are currently very limited.
"Today's approval marks a significant milestone in the development of the next generation of targeted medicines," said Briggs Morrison, executive vice president of global medicines development and chief medical officer at AstraZeneca.
"We are committed to bringing new treatments to the patients who need them most and today's news marks only the first of what we hope will be a number of indications in which Lynparza has the potential to transform the lives of cancer patients, including those with breast, pancreatic and gastric cancers."